Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?

doi:10.5497/wjp.v3.i4.72

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13359)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

988

WORD

359

HTML

8907

Figures (1-4)

585

Tables (1-1)

176

Sum=11015

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1122

Download

1222

Sum=2344

Dec 9, 2014 (publication date) through Jul 5, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Dec 9, 2014; 3(4): 72-85
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.72

Full Size Figure Download Figure

Figure 3 Schematic representation of mechanism of action of HER2-targeted drugs. PZ recognizes an epitope within the HER2 dimerization domain, thus preventing interaction with other activated ErbB receptors. Moreover PZ recruits natural killer cells, which mediate ADCC. TKI act on HER2 tyrosine kinase activity, by blocking intracellular signaling. TZ binds the juxtamembrane portion of HER2, thus preventing receptor cleavage and stimulating ADCC response and receptor degradation after endocytosis of the HER2-TZ complex. PZ: Pertuzumab; TZ: Trastuzumab; TKI: Tyrosine kinase inhibitors; ADCC: Antibody dependent cellular cytotoxicity; HER: Human epidermal growth factor receptor; ErbB: erythroblastic leukemia viral oncogene homolog.

Citation: Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3(4): 72-85
URL: https://www.wjgnet.com/2220-3192/full/v3/i4/72.htm
DOI: https://dx.doi.org/10.5497/wjp.v3.i4.72